Drug intelligence / Profile preview

dimethyl fumarate + ponesimod

Development stage: Discontinued
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of dimethyl fumarate and ponesimod for the treatment of relapsing forms of multiple sclerosis. Dimethyl fumarate activates the Nrf2 pathway to reduce oxidative stress and inflammation, while ponesimod is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that prevents lymphocytes from leaving lymph nodes, reducing their migration into the central nervous system. Preclinical studies showed synergistic effects in reducing disease severity and prevalence compared to either treatment alone.

Targets

EDG1 (Sphingosine-1-phosphate receptors)KEAP1 (Kelch-like ECH-associated protein 1)

Beyond the preview

Go deeper on dimethyl fumarate + ponesimod.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dimethyl fumarate + ponesimod.

Explore the full profile